How is the severity of Amyloid-Related Imaging Abnormalities with Edema (ARIA-E) graded on Magnetic Resonance Imaging (MRI)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 14, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

ARIA-E Severity Grading on MRI

ARIA-E severity is graded as mild, moderate, or severe based on standardized MRI scoring systems that assess the extent and distribution of parenchymal edema and sulcal effusions, with management decisions directly tied to these severity grades. 1

Severity Classification System

The most widely validated approach uses either a 3-point (SSAE-3) or 5-point (SSAE-5) severity scale based on the largest linear measurement of the lesion and its spatial dissemination 2:

Mild ARIA-E

  • Limited parenchymal T2 FLAIR hyperintensity
  • Minimal sulcal effusions
  • No significant mass effect
  • Typically asymptomatic 1

Moderate ARIA-E

  • Intermediate extent of parenchymal edema
  • Variable sulcal FLAIR hyperintensity
  • May present with or without symptoms 1
  • Requires close monitoring and possible treatment modification 1

Severe ARIA-E

  • Extensive parenchymal involvement across multiple brain regions
  • Significant mass effect on surrounding structures
  • Typically symptomatic presentation (headache, confusion, visual disturbances) 1, 3
  • Mandates treatment modification or discontinuation 1

Key Imaging Features to Assess

When grading ARIA-E severity, systematically evaluate 1:

  • Anatomic location and distribution across the 6 brain regions bilaterally (frontal, parietal, temporal, occipital, basal ganglia/thalamus, cerebellum/brainstem) 4
  • Extent of parenchymal T2 FLAIR hyperintensity - quantify the largest area of involvement 2
  • Presence and extent of sulcal FLAIR hyperintensity (non-suppression of CSF signal) 1, 4
  • Associated mass effect on surrounding structures 1

Validated Scoring Systems

SSAE-3 and SSAE-5 Scales

The 3-point and 5-point Severity Scales of ARIA-E have demonstrated excellent inter-reader reliability (Cohen's kappa 0.79 and 0.73 respectively) and are now used in most major Alzheimer's disease trials 2. These scales assign a 0-6 point score for each of 6 brain regions bilaterally, with total scores ranging 0-60 4.

The SSAE-3 is preferred for clinical practice as it provides adequate discrimination with simpler implementation compared to SSAE-5 2, 5.

Alternative: Barkhof Grand Total Scale (BGTS)

The BGTS correlates highly with SSAE scales, with high concordance when using SSAE-3 >1 corresponding to BGTS >3 (accuracy 0.85-0.93) 5. However, the SSAE scales are more practical for routine clinical use 2.

Technical MRI Requirements

Essential Sequences

All three sequences are mandatory for comprehensive ARIA assessment 1:

  • T2 FLAIR - primary sequence for detecting ARIA-E 6, 1
  • T2 GRE or SWI* - for concurrent ARIA-H detection 6, 1
  • DWI - to exclude acute ischemia and assess for restricted diffusion 1, 3

Scanner Specifications

  • Minimum field strength: 1.5T acceptable, though 3T provides greater sensitivity 6, 3
  • Slice thickness: ≤5mm 6
  • TE: ≥20ms for gradient echo sequences 6

Reading Standards and Pitfalls

Central Reading Preferred

Central reading by trained neuroradiologists with specific ARIA expertise is strongly preferred over local reads to ensure accuracy and inter-rater reliability 1. This is particularly important because:

  • Subtle ARIA-E can be easily missed on routine reads 6
  • Fulminant ARIA-E can be misidentified as subarachnoid hemorrhage or venous infarction 6
  • Variable diagnostic certainty is inherent - allowance for "possible" vs "definite" readings should be made 6

Common Pitfalls to Avoid

  • Do not exclude patients based on "possible" findings - only "definite" ARIA-E should trigger management changes 6
  • Recognize that very subtle asymptomatic ARIA-E may not have clinical consequences if missed 6
  • Serial MRI scans may be needed to change diagnostic confidence from "possible" to "definite" 6

Clinical Correlation

Management is determined by both MRI severity grade AND clinical symptoms, not MRI findings alone 1. Symptomatic moderate-to-severe ARIA-E may require corticosteroid treatment, while asymptomatic mild ARIA-E may only warrant closer monitoring 1, 3.

References

Guideline

Grading Severity of ARIA-E and ARIA-H on MRI

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Validation of 3- and 5-point severity scales to assess ARIA-E.

Alzheimer's & dementia (Amsterdam, Netherlands), 2023

Guideline

Management of Symptomatic ARIA-E in Lecanemab Infusion Therapy

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Comparing ARIA-E severity scales and effects of treatment management thresholds.

Alzheimer's & dementia (Amsterdam, Netherlands), 2022

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.